Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes

Inclusion Criteria: * Definitely diagnosed type 2 DM either before or during the current hospitalization and with complex coronary lesions * The coronary lesion is complied with the definition of complex type. (defined by protocol) * The investigator admitted patients which are suitable for implanting Firebird2 CoCr-alloyed Sirolimus-eluting stent(SES) * Patient or his/ her legal supervisor are provided with informed consents. Exclusion Criteria: * Women during pregnancy and breast-feeding; * ST-segment elevated MI occurred within 1 week; * Graft lesion after the coronary artery bypass graft(CABG) operation; * Patient with other brand of stent implanted; * LVEF ≤ 35%; * Renal insufficiency before operation (Serum creatinine ≥ 177umol/L) * Impaired fasting glucose（6.0mmol/L～7.0mmol/L）or impaired glucose tolerance（OGTT 2h blood glucose 7.8mmol/L～11.1mmol/L）patient; * Recent PCI within 6 months or previous intravascular radiotherapy; * Predicted life span is less than 12 months; * Patient allergic to the following materials: aspirin, heparin, Clopidogrel, CoCr alloy, contrast agent or sirolimus. * Recent participation of trial medication or other device study without endpoints completion or it is clinically interfering FIRE2-DIABETES study endpoints. * Considered by other investigators unsuitable for implanting Firebird2 CoCr-alloyed SES * Patients could not obey the study rules, such as not understanding the study manner, scope or its outcome, not cooperative, not providing the informed consent, not accepting follow-up, not finishing the whole study procedure.